UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC., MSN LABORATORIES PRIVATE LTD., and MSN PHARMACEUTICALS INC., Petitioners,
V.
BAUSCH HEALTH IRELAND LIMITED, Patent Owner.
Case IPR2022-00722 ¹ Patent 7,041,786

PETITIONERS' REQUEST FOR ORAL ARGUMENT 37 C.F.R. §42.70(a)

¹ IPR2023-00016 has been joined with this proceeding.



Petitioner Mylan Pharmaceuticals Inc. requests oral argument on the

unpatentability of claims 1-6 of U.S. Patent No. 7,041,786 as instituted and

briefed, as well as on any pending motions.

Petitioner requests 45 minutes per side of oral argument. The oral argument

is scheduled to be held June 14, 2023, pursuant to the September 14, 2022,

scheduling order (Paper No. 17). Because the order advised that at least two

judges will appear remotely by video, Petitioner Mylan believes oral argument

may be most efficiently held virtually by videoconference. However, Petitioner

Mylan is ready and willing to appear in person at the USPTO Regional Office in

San Jose if this would be helpful to the Board.

Respectfully submitted,

Date: May 3, 2023

/Jad A. Mills/

Jad A. Mills, Reg. No. 63,344

Counsel for Mylan Pharmaceuticals Inc.



CERTIFICATE OF SERVICE

I certify a true and correct copy of this paper was served today to the email correspondence addresses of the patent owner and the joinder petitioners as follows:

Justin J. Hasford justin.hasford@finnegan.com

Bryan C. Diner <u>bryan.diner@finnegan.com</u>

Joshua Goldberg joshua.goldberg@finnegan.com

Caitlin O'Connell <u>caitlin.o'connell@finnegan.com</u>

Kyu Yun Kim <u>kyuyun.kim@finnegan.com</u>

Kassandra Officer <u>kassandra.officer@finnegan.com</u>

and on MSN's counsel at:

Andrew Larsen <u>alarsen@merchantgould.com</u>

Melissa Hayworth <u>mhayworth@merchantgould.com</u>

Respectfully submitted,

Date: May 3, 2023 /Robyn Moriarty/

Robyn Moriarty

